XML 92 R64.htm IDEA: XBRL DOCUMENT v3.25.4
Goodwill and Intangible Assets (Additional Information) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
May 31, 2023
Aug. 22, 2022
Jul. 11, 2022
Goodwill [Line Items]            
Goodwill $ 17,905,000 $ 17,905,000        
Goodwill, impairment losses 0 0        
Future amortization expense, 2026 26,600,000          
Future amortization expense, 2027 26,600,000          
Future amortization expense, 2028 26,600,000          
Future amortization expense, 2029 26,600,000          
Future amortization expense, 2030 26,600,000          
Future amortization expense, thereafter 49,200,000          
Intangible Assets Abstract            
Amortization expense 26,277,000 $ 25,902,000 $ 21,784,000      
Basilea            
Intangible Assets Abstract            
Upfront fee 4,000,000          
In-process research and development | XACDURO            
Intangible Assets Abstract            
Intangible assets pertain to product rights and developed technologies       $ 68,700,000    
In-process research and development | NUZOLVENCE            
Intangible Assets Abstract            
Acquired Finite-Lived Intangible Asset, Residual Value 2,600,000          
La Jolla Pharmaceutical Company            
Goodwill [Line Items]            
Goodwill         $ 6,400,000  
Intangible Assets Abstract            
Intangible assets pertain to product rights and developed technologies 151,000,000          
Entasis            
Goodwill [Line Items]            
Goodwill           $ 11,500,000
Intangible Assets Abstract            
Intangible assets pertain to product rights and developed technologies 106,700,000          
Entasis | Collaboration agreement            
Intangible Assets Abstract            
Intangible assets pertain to product rights and developed technologies 35,400,000          
Entasis | In-process research and development            
Intangible Assets Abstract            
Intangible assets pertain to product rights and developed technologies $ 71,300,000